DOCSLIB.ORG

Non-Coding Variants Connect Enhancer Dysregulation with Nuclear Receptor Signaling in Hematopoietic Malignancies

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Non-Coding Variants Connect Enhancer Dysregulation with Nuclear Receptor Signaling in Hematopoietic Malignancies Non-Coding Variants Connect Enhancer Dysregulation with Nuclear Receptor Signaling in Hematopoietic Malignancies Kailong Li1,2,5, Yuannyu Zhang1,2,5, Xin Liu1,2,5, Yuxuan Liu1,2,5, Zhimin Gu1,2, Hui Cao1,2, Kathryn E. Dickerson1,2, Mingyi Chen3, Weina Chen3, Zhen Shao4, Min Ni1, Jian Xu1,2,* 1Children’s Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA 2Department of Pediatrics, Harold C. Simmons Comprehensive Cancer Center, and Hamon Center for Regenerative Science and Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA 3Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA 4Key Laboratory of Computational Biology, CAS-MPG Partner Institute for Computational Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200031, China 5These authors contributed equally *Corresponding Author: [email protected] (J.X.) Running Title: Non-Coding Variants in Hematopoietic Malignancies Figure S1. Workflow for the identification of non-coding variants in human leukemia (A) Schematic of the major steps in targeted resequencing and functional analysis of non-coding alterations. The detailed information about the samples, identified mutations and variant-associated CREs are shown on the right. (B) Flowchart is shown for the annotation of blood CRE repertories. (C) Flowchart is shown for the mutation discovery pipeline. Figure S2. Identification of non-coding variants and recurrently mutated CREs (A) Schematic of the mutation discovery pipeline for identifying high-confidence (Tier I) somatic SNVs and INDELs in tumor/normal paired AML samples. (B) Flowchart is shown for the identification of Tier II somatic SNVs and INDELs in other leukemia and lymphoma samples and cell lines. (C) Variant allele frequency (VAF) of the identified SNVs and INDELs in targeted sequencing. (D) Comparisons of gene mutations in this study and recently published WGS studies of AML samples from TCGA (1), ICGC (http://icgc.org), and Beat AML (3 batches of samples) (http://www.vizome.org) (2) cohorts. Both Tier I and II somatic gene mutations identified in targeted CRE sequencing are shown. (E) Flowchart is shown for the identification of recurrently mutated CREs. Figure S3. Analysis of coding and non-coding variants in human leukemia (A) Heatmap shows the recurrent protein-coding gene mutations identified by targeted resequencing in human leukemia. The gene symbols are shown on the left. The cumulative numbers of mutated samples for each gene are shown on the right. The numbers of mutated genes in each sample are shown on the top. Samples are categorized by disease types (AML or MDS, lymphoma, ALL and normal) and sources (patient and cell line) with each sample ID shown on the bottom. (B) Comparison of coding and non-coding mutation frequency between patient samples and cell lines. (C) Comparison of coding and non-coding mutation frequency between different leukemia types (AML, lymphoma and ALL) and normal controls. Results are means ± SD and analyzed by a one-way ANOVA. ***P < 0.001, n.s. not significant. (D) Comparison of coding and non-coding mutation frequency between different sites (BM vs PB), genders (male vs female), and FAB classification of AML subtypes (M0 to M4). Results are means ± SD and analyzed by a student’s t-test or one-way ANOVA. n.s. not significant. (E) Lack of correlation between mutation frequency and ages. All leukemia samples (purple) or AML samples (blue) are shown. Pearson correlation coefficient (R) and P values are shown. Figure S4. Development of the CRE perturbation screening systems (A) Flowchart is shown for the design of the sgRNA pool for CRE perturbation screening. (B) Validation of CRE perturbation screens by independent replicate experiments. CRE-specific sgRNAs (black) and non-targeting control sgRNAs (red) are shown. The x- and y-axis denote the log2 fold changes of sgRNA enrichment or dropout in T28 relative to T0 samples. The Pearson correlation coefficient (R) values are shown. (C) Comparisons of replicate experiments of enCRISPRa screening at different time points. The x- and y- axis of each graph represent the normalized sgRNA counts in enCRISPRa screens at day0 (T0) and day28 (T28). Spearman correlation value is shown for each comparison. (D) Comparisons of replicate experiments of enCRISPRi screening at different time points. (E) enCRISPRa-mediated activation of candidate oncogenic or tumor suppressive CREs resulted in significant enrichment or dropout of CRE-targeting sgRNAs, respectively. Box plots are shown for sgRNAs targeting oncogenic, tumor suppressive or other CREs, or non-targeting controls (x-axis) by the log2 fold changes of sgRNA enrichment or dropout in T28 relative to T0 samples (y-axis). Boxes show median of the data and quantiles, and whiskers extend to 1.5x of the interquartile range. P values were calculated by the Welch’s t-test. (F) enCRISPRi-mediated repression of candidate oncogenic or tumor suppressive CREs resulted in significant enrichment or dropout of CRE-targeting sgRNAs, respectively. A Tumor Suppressive Promoters Oncogenic Promoters CRE Chromosome Nearest CRE923 CRE19872 CRE18011 CRE210 CRE Chromosome Nearest ID coordinates genes E/P (BCAR3;MIR760) CRE9782 (TOX) (ZNF253) (SPEN;FLJ37453) ID coordinates genes E/P CRE1161 chr1:146696609-146697700 FMO5 P CRE2191 chr10:6622165-6623239 PRKCQ-AS1;PRKCQ P 2 CRE2191 (BSG) CRE15272 CRE13414 chr21:36261257-36262671 RUNX1 P CRE923 chr1:94312038-94313684 MIR760;BCAR3 P (PRKCQ-AS1; (LPP;LPP-AS2) CRE18973 chr7:75367805-75369511 HIP1 P CRE16157 chr4:183837553-183839385 DCTD P PRKC1Q) CRE676 chr1:47696820-47697746 TAL1 P CRE9782 chr19:571003-572971 BSG P CRE16157 CRE18528 chr7:6098255-6099259 EIF2AK1 P CRE13645 chr22:20747916-20748772 ZNF74 P (DCTD) CRE18532 chr7:6387722-6389229 FAM220A P CRE19872 chr8:60031112-60032935 TOX P CRE11749 chr2:85132395-85133594 TMSB10 P CRE18372 chr6:159289942-159291725 C6orf99 P CRE13645 CRE3461 chr11:58345090-58346561 ZFP91;ZFP91-CNTF;LPXN P CRE10392 chr19:19976653-19977762 ZNF253 P (ZNF74) CRE2336 chr10:27541273-27542255 LRRC37A6P P CRE15272 chr3:187871255-187872821 LPP;LPP-AS2 P 0 CRE19440 chr7:149157199-149158530 ZNF777 P CRE9362 chr17:80022771-80024344 DUS1L P CRE11619 chr2:65454438-65455887 ACTR2 P CRE15386 chr4:925395-926355 TMEM175;GAK P CRE14603 chr3:57741420-57742382 SLMAP P CRE3575 chr11:64084943-64085746 PRDX5;TRMT112 P CRE11193 chr2:9695628-9696614 ADAM17 P CRE10913 chr19:50379407-50381413 TBC1D17;AKT1S1 P CRE8469 chr17:18163661-18164706 MIEF2;FLII P CRE1243 chr1:151118617-151119720 SEMA6C P CRE1592 chr1:179334231-179335393 AXDND1 P CRE21622 chrX:51636112-51637065 MAGED1 P CRE6194 chr14:73393076-73394163 DCAF4 P CRE6288 chr14:81687251-81687975 GTF2A1 P CRE19307 chr7:130080230-130081447 CEP41 P CRE20879 chr9:104159977-104161656 ZNF189;MRPL50 P CRE4519 chr12:48099412-48100456 RPAP3 P -2 CRE2030 chr1:236030212-236031340 LYST P CRE8291 chr17:4699228-4700114 PSMB6 P CRE12525 chr2:220042083-220043315 FAM134A;CNPPD1 P CRE850 chr1:85039161-85040173 CTBS P CRE16028 chr4:141677432-141678382 TBC1D9 P CRE21853 chrX:102941837-102942975 MORF4L2;MORF4L2-AS1 P CRE9489 chr18:12750264-12751100 LOC100996324 P CRE20513 chr9:34611607-34612582 RPP25L P CRE8971 CRE1245 chr1:151137838-151139325 SCNM1;LYSMD1 P chr1:220219140-220220593 EPRS P CRE12502 chr2:218990178-218990892 CXCR2 P CRE1857 (MSI2) CRE1225 chr1:150265803-150266742 MRPS21 P CRE19253 chr7:117823550-117824621 LSM8 P CRE3624 chr11:65292339-65293467 SCYL1 P CRE726 chr1:54355079-54355938 YIPF1 P CRE16100 chr4:159593272-159594085 ETFDH;C4orf46 P -4 CRE2044 chr1:236958591-236959468 MTR P CRE829 chr1:78244796-78245875 FAM73A P CRE18528 CRE12149 chr2:153574105-153575086 ARL6IP6;PRPF40A P CRE210 chr1:16174350-16175665 SPEN;FLJ37453 P (EIF1AK1) CRE18532 CRE4969 chr12:104609311-104610168 TXNRD1 P CRE7300 chr16:685892-687101 C16orf13 P (FAM220A) CRE3651 chr11:65728616-65729612 SART1 P CRE9953 chr19:4638110-4640206 TNFAIP8L1 P CRE17909 chr6:74170579-74172329 MTO1 P CRE18581 chr7:16460306-16461220 ISPD P CRE676 CRE10400 chr19:20747733-20748908 ZNF737 P CRE296 chr1:24126114-24128109 GALE P (TAL1) CRE11736 chr2:75185312-75186150 POLE4 P CRE4612 chr12:53614787-53615630 RARG P CRE17233 chr6:2875435-2876320 SERPINB9P1 P CRE16355 chr5:40678875-40679834 PTGER4 P CRE18973 CRE20707 chr9:80911164-80912545 PSAT1 P CRE15384 chr4:774868-776706 LOC100129917 P -6 (HIP1) CRE8971 chr17:55334065-55335008 MSI2 P enCRISPRi, log2 Enrichment (T28/T0) CRE153 chr1:10269924-10271441 KIF1B P CRE20172 chr8:124428099-124429820 WDYHV1 P CRE11583 chr2:64067994-64068916 UGP2 P sgRNAs targeting: CRE4244 chr12:6930058-6931215 GPR162 P CRE15745 chr4:76911162-76912330 SDAD1 P CRE13414 CRE20486 chr9:32551244-32552657 TOPORS-AS1;TOPORS P chr19:12163235-12164016 ZNF878 P CRE11314 chr2:27631829-27633103 PPM1G P CRE10147 All other promoters (RUNX1) CRE7302 chr16:698362-699516 WDR90 P CRE15960 chr4:120987496-120988961 MAD2L1 P CRE17302 chr6:8064039-8065222 BLOC1S5 P CRE7905 chr16:67193183-67194371 FBXL8;TRADD P CRE11386 chr2:37898839-37899616 CDC42EP3 P Non-targeting controls CRE175 chr1:11865359-11866764 CLCN6;MTHFR P CRE8561 chr17:27139090-27140525 FAM222B P -8 CRE7304 chr16:729283-730989 STUB1 P CRE17861 chr6:53211832-53213718 ELOVL5 P Tumor suppressive promoters CRE19753 chr8:37552261-37553387 ZNF703 P CRE19118 chr7:100181388-100182161 FBXO24 P CRE1161 CRE13663 chr22:21983495-21984551 YDJC P CRE11652 chr2:69870283-69871432 AAK1 P Oncogenic promoters
Load more

Recommended publications
  • 1 Evidence for Gliadin Antibodies As Causative Agents in Schizophrenia
    1 Evidence for gliadin antibodies as causative agents in schizophrenia. C.J.Carter PolygenicPathways, 20 Upper Maze Hill, Saint-Leonard’s on Sea, East Sussex, TN37 0LG [email protected] Tel: 0044 (0)1424 422201 I have no fax Abstract Antibodies to gliadin, a component of gluten, have frequently been reported in schizophrenia patients, and in some cases remission has been noted following the instigation of a gluten free diet. Gliadin is a highly immunogenic protein, and B cell epitopes along its entire immunogenic length are homologous to the products of numerous proteins relevant to schizophrenia (p = 0.012 to 3e-25). These include members of the DISC1 interactome, of glutamate, dopamine and neuregulin signalling networks, and of pathways involved in plasticity, dendritic growth or myelination. Antibodies to gliadin are likely to cross react with these key proteins, as has already been observed with synapsin 1 and calreticulin. Gliadin may thus be a causative agent in schizophrenia, under certain genetic and immunological conditions, producing its effects via antibody mediated knockdown of multiple proteins relevant to the disease process. Because of such homology, an autoimmune response may be sustained by the human antigens that resemble gliadin itself, a scenario supported by many reports of immune activation both in the brain and in lymphocytes in schizophrenia. Gluten free diets and removal of such antibodies may be of therapeutic benefit in certain cases of schizophrenia. 2 Introduction A number of studies from China, Norway, and the USA have reported the presence of gliadin antibodies in schizophrenia 1-5. Gliadin is a component of gluten, intolerance to which is implicated in coeliac disease 6.
    [Show full text]
  • The Rac Gtpase in Cancer: from Old Concepts to New Paradigms Marcelo G
    Published OnlineFirst August 14, 2017; DOI: 10.1158/0008-5472.CAN-17-1456 Cancer Review Research The Rac GTPase in Cancer: From Old Concepts to New Paradigms Marcelo G. Kazanietz1 and Maria J. Caloca2 Abstract Rho family GTPases are critical regulators of cellular func- mislocalization of Rac signaling components. The unexpected tions that play important roles in cancer progression. Aberrant pro-oncogenic functions of Rac GTPase-activating proteins also activity of Rho small G-proteins, particularly Rac1 and their challenged the dogma that these negative Rac regulators solely regulators, is a hallmark of cancer and contributes to the act as tumor suppressors. The potential contribution of Rac tumorigenic and metastatic phenotypes of cancer cells. This hyperactivation to resistance to anticancer agents, including review examines the multiple mechanisms leading to Rac1 targeted therapies, as well as to the suppression of antitumor hyperactivation, particularly focusing on emerging paradigms immune response, highlights the critical need to develop ther- that involve gain-of-function mutations in Rac and guanine apeutic strategies to target the Rac pathway in a clinical setting. nucleotide exchange factors, defects in Rac1 degradation, and Cancer Res; 77(20); 5445–51. Ó2017 AACR. Introduction directed toward targeting Rho-regulated pathways for battling cancer. Exactly 25 years ago, two seminal papers by Alan Hall and Nearly all Rho GTPases act as molecular switches that cycle colleagues illuminated us with one of the most influential dis- between GDP-bound (inactive) and GTP-bound (active) forms. coveries in cancer signaling: the association of Ras-related small Activation is promoted by guanine nucleotide exchange factors GTPases of the Rho family with actin cytoskeleton reorganization (GEF) responsible for GDP dissociation, a process that normally (1, 2).
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • A GTP-State Specific Cyclic Peptide Inhibitor of the Gtpase Gαs
    bioRxiv preprint doi: https://doi.org/10.1101/2020.04.25.054080; this version posted April 27, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. A GTP-state specific cyclic peptide inhibitor of the GTPase Gαs Shizhong A. Dai1,2†, Qi Hu1,2†, Rong Gao3†, Andre Lazar1,4†, Ziyang Zhang1,2, Mark von Zastrow1,4, Hiroaki Suga3*, Kevan M. Shokat1,2* 5 1Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, 94158, USA 2Howard Hughes Medical Institute 3Department of Chemistry, Graduate School of Science, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan 10 4Department of Psychiatry, University of California, San Francisco, San Francisco, CA, 94158, USA *Correspondence to: [email protected], [email protected] †These authors contributed equally. 15 20 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.04.25.054080; this version posted April 27, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Abstract: The G protein-coupled receptor (GPCR) cascade leading to production of the second messenger cAMP is replete with pharmacologically targetable receptors and enzymes with the exception of the stimulatory G protein α subunit, Gαs.
    [Show full text]
  • Clinical Utility of Recently Identified Diagnostic, Prognostic, And
    Modern Pathology (2017) 30, 1338–1366 1338 © 2017 USCAP, Inc All rights reserved 0893-3952/17 $32.00 Clinical utility of recently identified diagnostic, prognostic, and predictive molecular biomarkers in mature B-cell neoplasms Arantza Onaindia1, L Jeffrey Medeiros2 and Keyur P Patel2 1Instituto de Investigacion Marques de Valdecilla (IDIVAL)/Hospital Universitario Marques de Valdecilla, Santander, Spain and 2Department of Hematopathology, MD Anderson Cancer Center, Houston, TX, USA Genomic profiling studies have provided new insights into the pathogenesis of mature B-cell neoplasms and have identified markers with prognostic impact. Recurrent mutations in tumor-suppressor genes (TP53, BIRC3, ATM), and common signaling pathways, such as the B-cell receptor (CD79A, CD79B, CARD11, TCF3, ID3), Toll- like receptor (MYD88), NOTCH (NOTCH1/2), nuclear factor-κB, and mitogen activated kinase signaling, have been identified in B-cell neoplasms. Chronic lymphocytic leukemia/small lymphocytic lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, Burkitt lymphoma, Waldenström macroglobulinemia, hairy cell leukemia, and marginal zone lymphomas of splenic, nodal, and extranodal types represent examples of B-cell neoplasms in which novel molecular biomarkers have been discovered in recent years. In addition, ongoing retrospective correlative and prospective outcome studies have resulted in an enhanced understanding of the clinical utility of novel biomarkers. This progress is reflected in the 2016 update of the World Health Organization classification of lymphoid neoplasms, which lists as many as 41 mature B-cell neoplasms (including provisional categories). Consequently, molecular genetic studies are increasingly being applied for the clinical workup of many of these neoplasms. In this review, we focus on the diagnostic, prognostic, and/or therapeutic utility of molecular biomarkers in mature B-cell neoplasms.
    [Show full text]
  • User's Manual Mobile Phone
    User’s Manual Mobile Phone Model: AM206 FCC ID: UOSAM206 1 TABLE OF CONTENT 1. BASIC INFORMATION .................... 6 1.1. BRIEF INTRODUCTION ........................................... 6 2. BEFORE USE ..................................... 7 2.1. NAME AND EXPLANATION OF EACH PART ............. 7 2.1.1. Appearance Sketch Map ........................... 7 2.1.2. Description of the Standby Pictures .......... 7 2.1.3. Description of Keys .................................. 8 2.2. INSTALL SIM CARD AND MEMORY CARD ........... 10 2.2.1. SIM Card ................................................. 10 2.2.2. Inserting and Taking out SIM Card ........ 11 2.2.3. Memory Card .......................................... 12 2.3. BATTERY ............................................................ 12 2.3.1. Install the Battery .................................... 12 2.3.2. Charging .................................................. 13 2.4. SECURITY PASSWORD ......................................... 14 2 3. QUICK USER GUIDE ..................... 15 3.1. DIAL A CALL ....................................................... 15 3.2. REJECT A CALL ................................................... 15 3.3. RECEIVE A CALL ................................................. 15 3.4. END A CALL ........................................................ 16 3.5. EMERGENCY SERVICES ....................................... 16 3.6. EXTENSION SPEED DIAL ..................................... 16 3.7. DIALED CALLS/MISSED CALLS/RECEIVED CALLS/REJECTED CALLS .............................................
    [Show full text]
  • Tumor Markers
    Tumor Markers Alan H.B. Wu, Ph.D. Professor, Laboratory Medicine, UCSF Section Chief, Clinical Chemistry, Toxicology, Pharmacogenomics Laboratory, SFGH Learning objectives • Know the ideal characteristics of a tumor marker • Understand the role of tumor markers for diagnosis and management of patients with cancer. • Know the emerging technologies for tumor markers • Understand the role of tumor markers for therapeutic selection How do we diagnose cancer today? Physical Examination Blood tests CT scans Biopsy Human Prostate Cancer Normal Blood Smear Chronic Myeloid Leukemia Death rates for cancer vs. heart disease New cancer cases per year Cancer Site or Type New Cases Prostate 218,000 Lung 222,500 Breast 207,500 Colorectal 149,000 Urinary system 131,500 Skin 68,770 Pancreas 43,100 Ovarian 22,000 Myeloma 20,200 Thyroid 44,700 Germ Cell 9,000 Types of Tumor Markers • Hormones (hCG; calcitonin; gastrin; prolactin;) • Enzymes (acid phosphatase; alkaline phosphatase; PSA) • Cancer antigen proteins & glycoproteins (CA125; CA 15.3; CA19.9) • Metabolites (norepinephrine, epinephrine) • Normal proteins (thyroglobulin) • Oncofetal antigens (CEA, AFP) • Receptors (ER, PR, EGFR) • Genetic changes (mutations/translocations, etc.) Characteristics of an ideal tumor marker • Specificity for a single type of cancer • High sensitivity and specificity for cancerous growth • Correlation of marker level with tumor size • Homogeneous (i.e., minimal post-translational modifications) • Short half-life in circulation Roles for tumor markers • Determine risk (PSA)
    [Show full text]
  • Supplementary Materials
    Supplementary materials Supplementary Table S1: MGNC compound library Ingredien Molecule Caco- Mol ID MW AlogP OB (%) BBB DL FASA- HL t Name Name 2 shengdi MOL012254 campesterol 400.8 7.63 37.58 1.34 0.98 0.7 0.21 20.2 shengdi MOL000519 coniferin 314.4 3.16 31.11 0.42 -0.2 0.3 0.27 74.6 beta- shengdi MOL000359 414.8 8.08 36.91 1.32 0.99 0.8 0.23 20.2 sitosterol pachymic shengdi MOL000289 528.9 6.54 33.63 0.1 -0.6 0.8 0 9.27 acid Poricoic acid shengdi MOL000291 484.7 5.64 30.52 -0.08 -0.9 0.8 0 8.67 B Chrysanthem shengdi MOL004492 585 8.24 38.72 0.51 -1 0.6 0.3 17.5 axanthin 20- shengdi MOL011455 Hexadecano 418.6 1.91 32.7 -0.24 -0.4 0.7 0.29 104 ylingenol huanglian MOL001454 berberine 336.4 3.45 36.86 1.24 0.57 0.8 0.19 6.57 huanglian MOL013352 Obacunone 454.6 2.68 43.29 0.01 -0.4 0.8 0.31 -13 huanglian MOL002894 berberrubine 322.4 3.2 35.74 1.07 0.17 0.7 0.24 6.46 huanglian MOL002897 epiberberine 336.4 3.45 43.09 1.17 0.4 0.8 0.19 6.1 huanglian MOL002903 (R)-Canadine 339.4 3.4 55.37 1.04 0.57 0.8 0.2 6.41 huanglian MOL002904 Berlambine 351.4 2.49 36.68 0.97 0.17 0.8 0.28 7.33 Corchorosid huanglian MOL002907 404.6 1.34 105 -0.91 -1.3 0.8 0.29 6.68 e A_qt Magnogrand huanglian MOL000622 266.4 1.18 63.71 0.02 -0.2 0.2 0.3 3.17 iolide huanglian MOL000762 Palmidin A 510.5 4.52 35.36 -0.38 -1.5 0.7 0.39 33.2 huanglian MOL000785 palmatine 352.4 3.65 64.6 1.33 0.37 0.7 0.13 2.25 huanglian MOL000098 quercetin 302.3 1.5 46.43 0.05 -0.8 0.3 0.38 14.4 huanglian MOL001458 coptisine 320.3 3.25 30.67 1.21 0.32 0.9 0.26 9.33 huanglian MOL002668 Worenine
    [Show full text]
  • Screening for Tumor Suppressors: Loss of Ephrin PNAS PLUS Receptor A2 Cooperates with Oncogenic Kras in Promoting Lung Adenocarcinoma
    Screening for tumor suppressors: Loss of ephrin PNAS PLUS receptor A2 cooperates with oncogenic KRas in promoting lung adenocarcinoma Narayana Yeddulaa, Yifeng Xiaa, Eugene Kea, Joep Beumera,b, and Inder M. Vermaa,1 aLaboratory of Genetics, The Salk Institute for Biological Studies, La Jolla, CA 92037; and bHubrecht Institute, Utrecht, The Netherlands Contributed by Inder M. Verma, October 12, 2015 (sent for review July 28, 2015; reviewed by Anton Berns, Tyler Jacks, and Frank McCormick) Lung adenocarcinoma, a major form of non-small cell lung cancer, injections in embryonic skin cells identified several potential tu- is the leading cause of cancer deaths. The Cancer Genome Atlas morigenic factors (14–16). None of the reported studies have analysis of lung adenocarcinoma has identified a large number of performed direct shRNA-mediated high-throughput approaches previously unknown copy number alterations and mutations, re- in adult mice recapitulating the mode of tumorigenesis in humans. quiring experimental validation before use in therapeutics. Here, we Activating mutations at positions 12, 13, and 61 amino acids in describe an shRNA-mediated high-throughput approach to test a set Kirsten rat sarcoma viral oncogene homolog (KRas) contributes of genes for their ability to function as tumor suppressors in the to tumorigenesis in 32% of lung adenocarcinoma patients (2) by background of mutant KRas and WT Tp53. We identified several activating downstream signaling cascades. Mice with the KRasG12D candidate genes from tumors originated from lentiviral delivery of allele develop benign adenomatous lesions with long latency to shRNAs along with Cre recombinase into lungs of Loxp-stop-Loxp- develop adenocarcinoma (17, 18).
    [Show full text]
  • The Effects of Oncogenic G12d Mutation on K-Ras Structure, Conformation and Dynamics
    bioRxiv preprint doi: https://doi.org/10.1101/178483; this version posted August 19, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. THE EFFECTS OF ONCOGENIC G12D MUTATION ON K-RAS STRUCTURE, CONFORMATION AND DYNAMICS Sezen Vatansever1, 2, 3, Zeynep H. Gümüş2, 3*, Burak Erman1* 1Department of Chemical and Biological Engineering, College of Engineering, Koç University, Rumelifeneri Yolu, 34450, Sarıyer, Istanbul, Turkey 2Department of Genetics and Genomics, 3Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY 10029 *Correspondence: [email protected] (B.E.) and [email protected] (Z.H.G.) ABSTRACT K-Ras is the most frequently mutated protein in human tumors. Activating K-Ras mutations drive cancer initiation, progression and drug resistance, directly leading to nearly a million deaths per year. To understand the mechanisms by which mutations alter K-Ras function, we need to understand their effects on protein dynamics. However, despite decades of research, how oncogenic mutations in K-Ras alter its conformation and dynamics remain to be understood. Here, we present how the most recurrent K-Ras oncogenic mutation, G12D, leads to structural, conformational and dynamical changes that lead to constitutively active K- Ras. We have developed a new integrated MD simulation data analysis approach to quantify such changes in a protein and applied it to K-Ras. Our results show that G12D mutation induces strong negative correlations between the fluctuations of SII and those of the P-loop, Switch I (SI) and α3 regions in K-RasG12D.
    [Show full text]
  • Brain Nuclear Receptors and Body Weight Regulation
    Brain nuclear receptors and body weight regulation Yong Xu, … , Bert W. O’Malley, Joel K. Elmquist J Clin Invest. 2017;127(4):1172-1180. https://doi.org/10.1172/JCI88891. Review Series Neural pathways, especially those in the hypothalamus, integrate multiple nutritional, hormonal, and neural signals, resulting in the coordinated control of body weight balance and glucose homeostasis. Nuclear receptors (NRs) sense changing levels of nutrients and hormones, and therefore play essential roles in the regulation of energy homeostasis. Understanding the role and the underlying mechanisms of NRs in the context of energy balance control may facilitate the identification of novel targets to treat obesity. Notably, NRs are abundantly expressed in the brain, and emerging evidence indicates that a number of these brain NRs regulate multiple aspects of energy balance, including feeding, energy expenditure and physical activity. In this Review we summarize some of the recent literature regarding effects of brain NRs on body weight regulation and discuss mechanisms underlying these effects. Find the latest version: http://jci.me/88891/pdf REVIEW SERIES: NUCLEAR RECEPTORS The Journal of Clinical Investigation Series Editor: Mitchell A. Lazar Brain nuclear receptors and body weight regulation Yong Xu,1,2 Bert W. O’Malley,2 and Joel K. Elmquist3 1Children’s Nutrition Research Center, Department of Pediatrics, and 2Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas, USA. 3Division of Hypothalamic Research, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA. Neural pathways, especially those in the hypothalamus, integrate multiple nutritional, hormonal, and neural signals, resulting in the coordinated control of body weight balance and glucose homeostasis.
    [Show full text]
  • Agonist-Induced Formation of Unproductive Receptor-G12 Complexes Najeah Okashaha, Shane C
    Agonist-induced formation of unproductive receptor-G12 complexes Najeah Okashaha, Shane C. Wrightb, Kouki Kawakamic, Signe Mathiasend,e,f, Joris Zhoub, Sumin Lua, Jonathan A. Javitchd,e,f, Asuka Inouec, Michel Bouvierb, and Nevin A. Lamberta,1 aDepartment of Pharmacology and Toxicology, Medical College of Georgia, Augusta University, Augusta, GA 30912; bInstitute for Research in Immunology and Cancer, Department of Biochemistry and Molecular Medicine, Université de Montréal, Montréal, QC H3T 1J4, Canada; cGraduate School of Pharmaceutical Sciences, Tohoku University, 980-8578 Sendai, Japan; dDepartment of Psychiatry, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032; eDepartment of Pharmacology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032; and fDivision of Molecular Therapeutics, New York State Psychiatric Institute, New York, NY 10032 Edited by Brian K. Kobilka, Stanford University School of Medicine, Stanford, CA, and approved July 24, 2020 (received for review February 28, 2020) G proteins are activated when they associate with G protein- association does not always promote G protein activation and coupled receptors (GPCRs), often in response to agonist-mediated may in some circumstances inhibit downstream signaling. receptor activation. It is generally thought that agonist-induced receptor-G protein association necessarily promotes G protein acti- Results vation and, conversely, that activated GPCRs do not interact with V2R Interacts with G12 Heterotrimers. Conventional GPCR-G pro- G proteins that they do not activate. Here we show that GPCRs can tein coupling is understood as an allosteric interaction where an form agonist-dependent complexes with G proteins that they do agonist-bound active receptor mediates GDP release by stabi- not activate.
    [Show full text]